Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid with or without bezafibrate for primary biliary cholangitis
NL-OMON54633Phase 2Recruiting
- Sponsor
- Intercept Pharmaceuticals
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid and bezafibrate in primary biliary cholangitis (PBC) (3 arms), sponsored by Intercept Pharmaceuticals. Primary endpoint: Absolute change in alkaline phosphatase. Started Feb 2022; status: recruiting.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON54633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54633.